MX2018016295A - Interferon porcino pegilado y metodos de utilizacion del mismo. - Google Patents
Interferon porcino pegilado y metodos de utilizacion del mismo.Info
- Publication number
- MX2018016295A MX2018016295A MX2018016295A MX2018016295A MX2018016295A MX 2018016295 A MX2018016295 A MX 2018016295A MX 2018016295 A MX2018016295 A MX 2018016295A MX 2018016295 A MX2018016295 A MX 2018016295A MX 2018016295 A MX2018016295 A MX 2018016295A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- pinf
- variants
- porcine interferon
- pegylated
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
En la presente se describen variantes de interferón alfa porcino (pIEN-a) que comprenden un aminoácido sintético en lugares seleccionados en pIFN-o y una o dos Inserciones de aminoácidos en el extremo amino terminal tras la eliminación del péptido señal. Las variantes de pIFN-a pueden estar pegiladas. También se proporcionan los métodos para preparar y administrar estos compuestos para tratar infecciones virares en cerdos y las formulaciones que comprenden las variantes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352163P | 2016-06-20 | 2016-06-20 | |
| PCT/US2017/037964 WO2017222940A1 (en) | 2016-06-20 | 2017-06-16 | Pegylated porcine interferon and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018016295A true MX2018016295A (es) | 2019-09-16 |
Family
ID=59258379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018016295A MX2018016295A (es) | 2016-06-20 | 2017-06-16 | Interferon porcino pegilado y metodos de utilizacion del mismo. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10960080B2 (es) |
| EP (1) | EP3471755B1 (es) |
| JP (2) | JP7093311B2 (es) |
| KR (2) | KR102409470B1 (es) |
| CN (2) | CN109641034B (es) |
| AU (2) | AU2017280958A1 (es) |
| BR (1) | BR112018076437A2 (es) |
| CA (1) | CA3028683A1 (es) |
| CL (1) | CL2018003697A1 (es) |
| DK (1) | DK3471755T3 (es) |
| EA (1) | EA036509B1 (es) |
| ES (1) | ES2793773T3 (es) |
| MX (1) | MX2018016295A (es) |
| NZ (1) | NZ749962A (es) |
| PL (1) | PL3471755T3 (es) |
| PT (1) | PT3471755T (es) |
| WO (1) | WO2017222940A1 (es) |
| ZA (1) | ZA201808352B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP4141002A1 (en) | 2015-11-19 | 2023-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| PL3394033T3 (pl) | 2015-12-22 | 2021-05-31 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
| TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| MA45116A (fr) | 2016-05-26 | 2021-06-02 | Incyte Corp | Composés hétérocycliques comme immunomodulateurs |
| MX2018016273A (es) | 2016-06-20 | 2019-07-04 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| MD3558990T2 (ro) | 2016-12-22 | 2023-02-28 | Incyte Corp | Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1 |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| CN110582493B (zh) | 2016-12-22 | 2024-03-08 | 因赛特公司 | 作为免疫调节剂的苯并噁唑衍生物 |
| EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| SG11202009440WA (en) | 2018-03-30 | 2020-10-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| DK3790877T3 (da) | 2018-05-11 | 2023-04-24 | Incyte Corp | Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer |
| WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| CN110343164A (zh) * | 2019-08-22 | 2019-10-18 | 安阳工学院 | 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用 |
| US11401279B2 (en) | 2019-09-30 | 2022-08-02 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| TW202120504A (zh) | 2019-11-11 | 2021-06-01 | 美商英塞特公司 | Pd-1/pd-l1 抑制劑之鹽及結晶型 |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| AU2021373044A1 (en) | 2020-11-06 | 2023-06-08 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
| CN113845599B (zh) * | 2021-11-01 | 2023-09-19 | 长春萤火虫生物科技有限公司 | 一种重组猪干扰素融合蛋白及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858409B1 (en) * | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
| PT730470E (pt) * | 1993-11-10 | 2002-08-30 | Enzon Inc | Conjugados melhorados de interferao-polimero |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US20050226845A1 (en) * | 2004-03-10 | 2005-10-13 | Chih-Ping Liu | Method of treatment using interferon-tau |
| JP2006213597A (ja) * | 2000-07-19 | 2006-08-17 | Pepgen Corp | インターフェロン−タウを用いるｃ型肝炎ウイルスの処置のための組成物およびモニタリングの方法 |
| AU2005211362B2 (en) | 2004-02-02 | 2008-03-13 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
| ATE529442T1 (de) | 2005-06-03 | 2011-11-15 | Ambrx Inc | Verbesserte humane interferon-moleküle und ihre verwendungen |
| US7695710B2 (en) | 2005-06-20 | 2010-04-13 | Pepgen Corporation | Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs |
| PL2195338T3 (pl) | 2007-10-01 | 2014-05-30 | Pharmaessentia Corp | Interferon alfa zmodyfikowany na końcu N |
| US10138283B2 (en) | 2008-07-23 | 2018-11-27 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
| CN104262480B (zh) | 2014-09-28 | 2018-03-27 | 重庆理工大学 | 重组猪长效‑α干扰素的构建和修饰方法及其冻干注射剂的制备方法 |
-
2017
- 2017-06-16 AU AU2017280958A patent/AU2017280958A1/en not_active Abandoned
- 2017-06-16 CN CN201780051072.0A patent/CN109641034B/zh active Active
- 2017-06-16 NZ NZ749962A patent/NZ749962A/en unknown
- 2017-06-16 ES ES17734584T patent/ES2793773T3/es active Active
- 2017-06-16 KR KR1020187036853A patent/KR102409470B1/ko active IP Right Grant
- 2017-06-16 PL PL17734584T patent/PL3471755T3/pl unknown
- 2017-06-16 US US16/311,540 patent/US10960080B2/en active Active
- 2017-06-16 EP EP17734584.0A patent/EP3471755B1/en active Active
- 2017-06-16 CA CA3028683A patent/CA3028683A1/en active Pending
- 2017-06-16 EA EA201892671A patent/EA036509B1/ru unknown
- 2017-06-16 BR BR112018076437A patent/BR112018076437A2/pt unknown
- 2017-06-16 PT PT177345840T patent/PT3471755T/pt unknown
- 2017-06-16 DK DK17734584.0T patent/DK3471755T3/da active
- 2017-06-16 KR KR1020227019809A patent/KR102518451B1/ko active IP Right Grant
- 2017-06-16 WO PCT/US2017/037964 patent/WO2017222940A1/en unknown
- 2017-06-16 MX MX2018016295A patent/MX2018016295A/es unknown
- 2017-06-16 JP JP2018566519A patent/JP7093311B2/ja active Active
- 2017-06-16 CN CN202310995289.4A patent/CN117024562A/zh active Pending
-
2018
- 2018-12-11 ZA ZA2018/08352A patent/ZA201808352B/en unknown
- 2018-12-19 CL CL2018003697A patent/CL2018003697A1/es unknown
-
2021
- 2021-02-26 US US17/186,642 patent/US20210177980A1/en active Pending
- 2021-09-06 AU AU2021229132A patent/AU2021229132B2/en active Active
-
2022
- 2022-06-17 JP JP2022098147A patent/JP7441892B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210177980A1 (en) | 2021-06-17 |
| NZ749962A (en) | 2020-06-26 |
| WO2017222940A1 (en) | 2017-12-28 |
| CL2018003697A1 (es) | 2019-05-10 |
| CA3028683A1 (en) | 2017-12-28 |
| CN109641034A (zh) | 2019-04-16 |
| ES2793773T3 (es) | 2020-11-16 |
| US20190192673A1 (en) | 2019-06-27 |
| JP7441892B2 (ja) | 2024-03-01 |
| ZA201808352B (en) | 2020-08-26 |
| PL3471755T3 (pl) | 2020-10-19 |
| US10960080B2 (en) | 2021-03-30 |
| KR20220086700A (ko) | 2022-06-23 |
| KR102518451B1 (ko) | 2023-04-04 |
| CN117024562A (zh) | 2023-11-10 |
| KR102409470B1 (ko) | 2022-06-16 |
| AU2017280958A1 (en) | 2018-12-20 |
| EP3471755A1 (en) | 2019-04-24 |
| BR112018076437A2 (pt) | 2019-10-01 |
| JP2022137063A (ja) | 2022-09-21 |
| JP2019519553A (ja) | 2019-07-11 |
| EA036509B1 (ru) | 2020-11-18 |
| CN109641034B (zh) | 2023-08-15 |
| JP7093311B2 (ja) | 2022-06-29 |
| KR20190039889A (ko) | 2019-04-16 |
| AU2021229132A1 (en) | 2021-09-30 |
| EA201892671A1 (ru) | 2019-05-31 |
| EP3471755B1 (en) | 2020-04-22 |
| DK3471755T3 (da) | 2020-05-18 |
| AU2021229132B2 (en) | 2023-04-06 |
| PT3471755T (pt) | 2020-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ749962A (en) | Pegylated porcine interferon and methods of use thereof | |
| PH12019501414A1 (en) | Amino acid compositions and methods for the treatment of liver diseases | |
| MX2017004488A (es) | Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso. | |
| WO2017009843A3 (en) | Compositions, articles of manufacture and methods for treating cancer | |
| MX2016012799A (es) | Metodos para tratar el virus de la hepatitis c. | |
| SG11201912103TA (en) | Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases | |
| MX2018011162A (es) | Metodos de purificacion de colageno 7. | |
| MX2021008207A (es) | Proteínas de fusión multifuncionales y usos de las mismas. | |
| ZA202007834B (en) | Compositions comprising amino acids for use in the prevention and treatment of liver diseases | |
| MX2018000240A (es) | Metodos para tratar el vhc. | |
| MX2023000804A (es) | Peptidos para usarse en la promocion del transporte de glucosa. | |
| NZ756128A (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| EP2552462A4 (en) | CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE | |
| WO2015168488A3 (en) | Islet amyloid polypeptides with improved solubility | |
| IN2014CN00510A (es) | ||
| MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
| NZ700467A (en) | Treatments suitable for malassezia infections | |
| IN2015DN01371A (es) | ||
| IL287987A (en) | Improved dried formulations relating to hyaluronic acid and plasmatic proteins, and their uses | |
| MX2019012083A (es) | Nueva vacuna de peptidos contra la pcsk9. | |
| GB201018125D0 (en) | Peptide | |
| SG11201912098SA (en) | Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases | |
| GB2517871A (en) | Alternaria peptides | |
| EA202092368A1 (ru) | Применение происходящих из pedf коротких пептидов при заживлении сухожилий | |
| EA202092366A1 (ru) | Применение происходящих из pedf коротких пептидов при лечении остеоартрита |